Relief Therapeutics Holding AG and FirstString Research Inc. Announce a Strategic Collaboration for the Development of Atexakin Alfa
Relief Therapeutics Holding AG (“Relief”, SIX: RLF), a biotechnology company dedicated to the clinical development of innovative molecules for the treatment of certain complications of Diabetes and of respiratory diseases, announces today, a strategic collaboration agreement between its subsidiary Relief Therapeutics SA and FirstString Research Inc. for the support of the clinical development in the United States of atexakin alfa, a low-dose formulation of recombinant human interleukin 6 (rhIL-6). Under the terms of this collaboration agreement, FirstString will seek US government financial support, develop relevant collaborations, and provide resources towards the Food and Drug Administration (FDA) requirements on the constitution of an Investigational New Drug (IND) application dossier for atexakin alfa in Diabetic Neuropathy. This collaboration is in line with the intention of both companies, operating in the area of diabetic complications, to develop a stronger research and commercial relationship.
Gaël Hédou, CEO of Relief Therapeutics SA declares: “We are delighted to take a concrete step toward an effective collaboration with FirstString. Not only will it allow us to progress atexakin alfa toward its clinical development in the US, but it anticipates our future company growth that is planned with FirstString”.
Gautam Ghatnekar, CEO of FirstString Research states: “We are excited to help advance the development of atexakin alfa in North America. Atexakin has shown tremendous potential to alleviate neuropathy, which would help diabetic patients in need of an efficient treatment. This collaboration with the Relief Therapeutics team constitutes a clear commitment on both sides to work on building a stronger strategic partnership”.
About atexakin alfa:
Atexakin alfa has originally been developed by Merck KGaA which licensed the worldwide rights to develop, manufacture and commercialize the compound to Relief Therapeutics in August 2015. Atexakin alfa has the potential to fulfill an unmet medical need in Diabetic Neuropathy by regenerating damaged nerve fibers, remyelination and reduction of neuropathic symptoms. Relief Therapeutics is currently designing and planning to test the compound in a phase II clinical trial to assess safety and efficacy as a disease modifier for Diabetic Neuropathy.
About Relief Therapeutics:
RELIEF THERAPEUTICS Holding AG is a clinical-stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two most promising drug candidates are aviptadil for the treatment of sarcoidosis (already in Phase III) and low dose interleukin-6 (atexakin alfa) for the treatment of peripheral diabetic neuropathy (already in Phase II). Aviptadil development in sarcoidosis focuses the drug on an orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin alfa is the subject of an exclusive worldwide development and commercialization agreement with a division of the global established pharmaceutical firm Merck KGaA and has been the subject of multiple clinical trials representing a major capital investment. Based on its unique mechanism of action, atexakin alfa could become the first regenerative therapeutic for peripheral neuropathy. The peripheral diabetic neuropathy market is estimated to reach $4.1 billion in 2019, according to Datamonitor.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and is headquartered in Zurich, Switzerland.
For more information, please visit: www.relieftherapeutics.com
About FirstString Research Inc.:
FirstString Research, Inc. is a privately held biopharmaceutical company located in Mt. Pleasant, South Carolina. FirstString is dedicated to delivering breakthrough solutions for inflammation-based medical conditions through an in-depth understanding of the molecular and cellular contexts that define the underlying pathology. The company’s lead product, Granexin® gel (aCT1), is a novel, proprietary peptide mimetic of the C-terminus of connexin43 that has shown to play a fundamental role in processes that are critical to inflammation and injury response. Granexin® gel has demonstrated statistically significant and clinically meaningful efficacy with good safety in one Phase 1 and three Phase 2 placebo-controlled, randomized, double-blinded clinical trials and is poised to enter Phase 3 development for the treatment of diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Our clinical development strategies and product pipeline are based upon insights from biological context resulting in the validation of therapeutic potential for novel indications with earlier RoI prospects.
For more information, please visit: www.firststringresearch.com
Disclaimer:
This news release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, the completion of clinical trials, the FDA and other foreign review processes and other governmental regulation, RELIEF THERAPEUTICS Holding AG abilities to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, the ability to effectively market products, and other factors. Relief Therapeutics undertakes no duty to update forward looking statements nor can be taken responsible in any manner if such statements are not verified in the future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006042/en/
Contact information
FirstString Research:
info@firststringresearch.com
or
RELIEF
THERAPEUTICS Holding AG
Dr. Raghuram Selvaraju
Investor
Relations
Tel: +41 44 723 59 59
investors@relieftherapeutics.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo